143 related articles for article (PubMed ID: 11182226)
1. MHC haplotypes affect the expression of opportunistic infections in HIV patients.
Price P; Keane NM; Stone SF; Cheong KY; French MA
Hum Immunol; 2001 Feb; 62(2):157-64. PubMed ID: 11182226
[TBL] [Abstract][Full Text] [Related]
2. Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy.
Price P; Mathiot N; Krueger R; Stone S; Keane NM; French MA
J Clin Virol; 2001 Oct; 22(3):279-87. PubMed ID: 11564593
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases.
Price P; Morahan G; Huang D; Stone E; Cheong KY; Castley A; Rodgers M; McIntyre MQ; Abraham LJ; French MA
AIDS; 2002 Oct; 16(15):2043-7. PubMed ID: 12370503
[TBL] [Abstract][Full Text] [Related]
4. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.
Lazaro E; Coureau G; Guedj J; Blanco P; Pellegrin I; Commenges D; Dabis F; Moreau JF; Pellegrin JL; Thiébaut R;
Antivir Ther; 2006; 11(3):343-50. PubMed ID: 16759051
[TBL] [Abstract][Full Text] [Related]
5. Immune restoration disease: a consequence of dysregulated immune responses after HAART.
Stone SF; Price P; French MA
Curr HIV Res; 2004 Jul; 2(3):235-42. PubMed ID: 15279587
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy.
Keane NM; Price P; Lee S; Stone SF; French MA
Clin Exp Immunol; 2001 Oct; 126(1):111-6. PubMed ID: 11678906
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral therapy. Immune restoration disease in HIV-infected patients on HAART.
French MA
AIDS Read; 1999 Nov; 9(8):548-9, 554-5, 559-62. PubMed ID: 11082733
[TBL] [Abstract][Full Text] [Related]
8. Analysis of TACI mutations in CVID & RESPI patients who have inherited HLA B*44 or HLA*B8.
Waldrep ML; Zhuang Y; Schroeder HW
BMC Med Genet; 2009 Sep; 10():100. PubMed ID: 19775471
[TBL] [Abstract][Full Text] [Related]
9. Immune predispositions for cytomegalovirus retinitis in AIDS. The HNRC Group.
Schrier RD; Freeman WR; Wiley CA; McCutchan JA
J Clin Invest; 1995 Apr; 95(4):1741-6. PubMed ID: 7706482
[TBL] [Abstract][Full Text] [Related]
10. B-cell numbers in the blood of patients with non-HLA*B8 or non-HLA*B44 common variable immunodeficiency.
Johnston DT; Schroeder HW
Ann Allergy Asthma Immunol; 2007 Feb; 98(2):163-7. PubMed ID: 17304884
[TBL] [Abstract][Full Text] [Related]
11. Disseminated mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?
Lange CG; Woolley IJ; Brodt RH
Drugs; 2004; 64(7):679-92. PubMed ID: 15025543
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis.
Whitcup SM; Fortin E; Lindblad AS; Griffiths P; Metcalf JA; Robinson MR; Manischewitz J; Baird B; Perry C; Kidd IM; Vrabec T; Davey RT; Falloon J; Walker RE; Kovacs JA; Lane HC; Nussenblatt RB; Smith J; Masur H; Polis MA
JAMA; 1999 Nov; 282(17):1633-7. PubMed ID: 10553789
[TBL] [Abstract][Full Text] [Related]
13. Identification of HLA-B44 subtypes associated with extended MHC haplotypes.
Kruskall MS; Eynon EE; Awdeh Z; Alper CA; Yunis EJ
Immunogenetics; 1987; 26(4-5):216-9. PubMed ID: 3653939
[TBL] [Abstract][Full Text] [Related]
14. Survival and HLA-B*57 in HIV/HCV Co-Infected Patients on Highly Active Antiretroviral Therapy (HAART).
Dold L; Ahlenstiel G; Althausen E; Luda C; Schwarze-Zander C; Boesecke C; Wasmuth JC; Rockstroh JK; Spengler U
PLoS One; 2015; 10(8):e0134158. PubMed ID: 26241854
[TBL] [Abstract][Full Text] [Related]
15. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis.
Komanduri KV; Feinberg J; Hutchins RK; Frame RD; Schmidt DK; Viswanathan MN; Lalezari JP; McCune JM
J Infect Dis; 2001 Apr; 183(8):1285-9. PubMed ID: 11262214
[TBL] [Abstract][Full Text] [Related]
16. CMV-specific immune responses and HLA phenotypes of AIDS patients who develop CMV retinitis. HNRC Group. HIV Neurobehavioral Research Center.
Schrier RD; Freeman WR; Wiley CA; McCutchan JA
Adv Neuroimmunol; 1994; 4(3):327-36. PubMed ID: 7874401
[TBL] [Abstract][Full Text] [Related]
17. Impact of highly active antiretroviral therapy on onset of Mycobacterium avium complex infection and cytomegalovirus disease in patients with AIDS.
Baril L; Jouan M; Agher R; Cambau E; Caumes E; Bricaire F; Katlama C
AIDS; 2000 Nov; 14(16):2593-6. PubMed ID: 11101072
[TBL] [Abstract][Full Text] [Related]
18. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.
Keane NM; Price P; Lee S; Almeida CA; Stone SF; James I; French MA
HIV Med; 2004 Nov; 5(6):407-14. PubMed ID: 15544692
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus.
Villacres MC; Lacey SF; La Rosa C; Krishnan R; Auge C; Longmate J; Zaia JA; Leedom JM; Diamond DJ
J Infect Dis; 2001 Aug; 184(3):256-67. PubMed ID: 11443550
[TBL] [Abstract][Full Text] [Related]
20. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy.
Kirk O; Reiss P; Uberti-Foppa C; Bickel M; Gerstoft J; Pradier C; Wit FW; Ledergerber B; Lundgren JD; Furrer H;
Ann Intern Med; 2002 Aug; 137(4):239-50. PubMed ID: 12186514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
